Abstract：Objective To analyze the clinical efficacy of mosapride combined with Weifuchun capsules in the treatment of functional dyspepsia.  Methods A total of 116 patients with functional dyspepsia treated in our hospital from March 2019 to January 2020 were randomly divided into a control group and an observation group, with 58 cases in each group. The control group was treated with oral mosapride, while the observation group received additional treatment with Weifuchun capsules on the basis of the control group, with both groups undergoing a 2-month treatment course. The clinical efficacy, Traditional Chinese Medicine （TCM） symptom scores, levels of serum pepsinogen, immune function, and incidence of adverse reactions were compared between the two groups.  Results The total effective rate and cure rate in the observation group were significantly higher than those in the control group （χ2＝9.265, 7.315, both P＜0.05）. Post-treatment TCM symptom scores, levels of pepsinogen, CD4＋T lymphocytes, CD8＋T lymphocytes, and the CD4＋/CD8＋ ratio in the observation group were significantly better than those in the control group, with statistically significant differences between the groups （t＝9.37, 7.54, 8.51, 8.34, 5.68, 4.75, 8.71, 5.34, 6.23, 7.76, all P＜0.05）. There was no significant difference in the incidence of adverse reactions between the two groups （P＞0.05）. Conclusion The combination of mosapride and Weifuchun capsules has a significant clinical effect in treating functional dyspepsia, enhancing pepsinogen secretion, and regulating immune function, with a high safety profile.